Table 1.
Baseline clinical characteristics of the study population (N = 505).
| Total (n = 505) | <80 years (n = 459) | ≥80 years (n = 46) | p‐Value | |
|---|---|---|---|---|
| Age, mean (SD), years | 69.5 (7.7) | 68.2 (6.9) | 82.3 (0.3) | <0.001 |
| Female, No. (%) | 230 (45.5) | 209 (45.5) | 21 (45.7) | 1 |
| BMI, mean (SD), kg/m2 | 25.0 (3.5) | 25.0 (3.5) | 24.2 (3.2) | 0.15 |
| Paroxysmal AF, No. (%) | 232 (45.9) | 207 (45.1) | 25 (54.3) | <0.001 |
| Hypertension, No. (%) | 379 (75) | 347 (75.6) | 32 (69.6) | 0.38 |
| Diabetes mellitus, No. (%) | 120 (23.8) | 109 (23.7) | 11 (23.9) | 1 |
| Coronary disease, No. (%) | 96 (19) | 87 (19.0) | 9 (19.6) | 0.85 |
| Heart failure, No. (%) | 44 (8.7) | 40 (8.7) | 4 (8.7) | 1 |
| History of Strok/TIA, No. (%) | 134 (26.5) | 122 (26.6) | 12 (26.1) | 1 |
| CHA2DS2VASc score, mean (SD) | 3.2 (1.4) | 3.1 (1.4) | 4.1 (1.3) | <0.001 |
| HAS‐BLED score, mean (SD) | 2.2 (1.1) | 2.2 (1.1) | 2.2 (0.9) | 0.98 |
| Antiarrhythmic therapy, No. (%) | ||||
| Class I, No. (%) | 30 (5.9) | 27 (5.9) | 3 (6.5) | 0.75 |
| Class II, No. (%) | 188 (37.2) | 173 (37.7) | 15 (32.6) | 0.53 |
| Class III, No. (%) | 74 (14.7) | 67 (14.6) | 7 (15.2) | 0.83 |
| Anticoagulation, No. (%) | 0.31 | |||
| Warfarin | 132 (26.1) | 124 (27.0) | 8 (17.4) | |
| NOAC | 66 (13.1) | 58 (12.6) | 8 (17.4) | |
| Antiplatelet therapy, No. (%) | 105 (20.8) | 96 (20.9) | 9 (19.6) | 1 |
| EF, mean (SD), % | 63.4 (6.2) | 63.3 (6.1) | 63.6 (6.5) | 0.78 |
| LA, mean (SD), % | 42.7 (6.1) | 42.7 (6.1) | 42.4 (5.5) | 0.79 |
| LVDD, mean (SD), % | 49.2 (4.9) | 49.2 (4.7) | 49.3 (6.2) | 0.86 |
| LVDS, mean (SD), % | 32.4 (4.3) | 32.4 (4.4) | 32.4 (4.1) | 0.99 |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); LA, left atrium; LVDD, left ventricular end diastolic diameter; LVDS, left ventricular end systolic diameter; LVEF, left ventricular ejection fraction; NOAC, nonvitamin K antagonist oral anticoagulants; TIA, transient ischemic attack.